19:07 , Nov 9, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Synthetic chemistry; conjugates A method for linking methionine residues to small molecules could be used to generate novel therapeutic protein-drug conjugates. The method involves two steps: adding a diazo-iodonium salt to a protein or...
19:44 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Conjugating ASOs to a GLP-1R agonist construct could enhance the delivery of antisense therapies to pancreatic islet β cells for metabolic diseases. The conjugates consist of 5’-hexylamino ASOs against the selected therapeutic...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
16:24 , Feb 9, 2018 |  BC Week In Review  |  Company News

Intarcia terminates late-stage diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an NDA seeking approval...
23:40 , Feb 2, 2018 |  BC Extra  |  Company News

Intarcia terminates Phase III diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials earlier this week evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an...
21:52 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends label update to AZ's Bydureon

EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include treatment of Type II diabetes in combination with other glucose lowering treatments, including basal insulin, when use of Bydureon...
19:54 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Intarcia gets CRL for Type II diabetes candidate ITCA 650

FDA issued a complete response letter to an NDA for ITCA 650 from Intarcia Therapeutics Inc. (Boston, Mass.) to treat Type II diabetes. The company said it plans to resubmit the NDA after meeting with...
23:09 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

AZ's Bydureon improves motor function in Phase II for PD

Data published in...
22:01 , Jun 21, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers PEG-based hydrogel microspheres that release peptide drugs continuously over several weeks could help treat Type II diabetes and other chronic diseases with once-monthly dosing. The microspheres are linked to peptide therapeutics via a...